Zigozard 25mg & 100mg Powder for Concentrate for Solution for Infusion
PDF Leaflet Revision Date: 21 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific hematological malignancies.
Dosage (summary)
IV infusion over 30-60 mins; 100 mg/mu00b2 on days 1-2 for CLL; 90 mg/mu00b2 + rituximab for NHL.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Live vaccines
- QT prolonging drugs
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
Common side effects
- Myelosuppression
- Infections
- Skin reactions
Counselling Points
- Report signs of infection
- Monitor for skin reactions
- Avoid live vaccines
Serious warnings
- Myelosuppression monitoring required
- Risk of opportunistic infections
- Hepatitis B reactivation
Important Disclaimer
The Zigozard 25mg & 100mg Powder for Concentrate for Solution for Infusion professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
